Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 19, 2018 (9 years ago)

Sterilized water for injections BP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Marketed Without An Approved NDA/ANDA: Flawless Beauty, LLC is voluntarily recalling all lots of different products sold individually or as part of multi-unit kits in accordance with Consent Decree of Permanent Injunction ordered by the United States District Court due to misbranding and unapproved new drugs pursuant to the FD&C Act.

Cause type: Unapproved drug

The product was marketed without an approved NDA/ANDA, or does not meet the OTC monograph it claims to follow. Nothing about the product - dose, purity, safety - has been reviewed by FDA, so the claims on the box are unverified. All unapproved drug recalls.

What was recalled

Sterilized water for injections BP, 50 x 5 mL plastic ampules, Manufactured in India

Recalling firm
Flawless Beauty LLC
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0332-2018 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by Flawless Beauty LLC

All 2018 recalls
Class II · Moderate risk

TAD Glutathione Whitening Kits lyophilized powder for injection

Marketed Without An Approved NDA/ANDA: Flawless Beauty, LLC is voluntarily recalling all lots of different products sold individually or as part of multi-unit kits in accordance with Consent Decree of Permanent Injunction ordered by the United States District Court due to misbranding and unapproved new drugs pursuant to the FD&C Act.

Terminated Unapproved drug Flawless Beauty LLC D-0335-2018
Class II · Moderate risk

Saluta Glutathione Whitening kits

Marketed Without An Approved NDA/ANDA: Flawless Beauty, LLC is voluntarily recalling all lots of different products sold individually or as part of multi-unit kits in accordance with Consent Decree of Permanent Injunction ordered by the United States District Court due to misbranding and unapproved new drugs pursuant to the FD&C Act.

Terminated Unapproved drug Flawless Beauty LLC D-0334-2018
Class II · Moderate risk

Ling Zhi capsules

Marketed Without An Approved NDA/ANDA: Flawless Beauty, LLC is voluntarily recalling all lots of different products sold individually or as part of multi-unit kits in accordance with Consent Decree of Permanent Injunction ordered by the United States District Court due to misbranding and unapproved new drugs pursuant to the FD&C Act.

Terminated Unapproved drug Flawless Beauty LLC D-0333-2018
Class II · Moderate risk

TP Drug Laboratories Vitamin C ampules

Marketed Without An Approved NDA/ANDA: Flawless Beauty, LLC is voluntarily recalling all lots of different products sold individually or as part of multi-unit kits in accordance with Consent Decree of Permanent Injunction ordered by the United States District Court due to misbranding and unapproved new drugs pursuant to the FD&C Act.

Terminated Unapproved drug Flawless Beauty LLC D-0331-2018

Other unapproved drug recalls from 2018

All unapproved drug recalls
Class II · Moderate risk

My Way (levonorgestrel)

Marketed Without an Approved NDA/ANDA: 2-pack configuration did not receive appropriate regulatory approval prior to release.

Terminated Unapproved drug Lupin Pharmaceuticals Inc. D-0838-2018
Class II · Moderate risk

My Way (Levonorgestrel)

Marketed Without an Approved NDA/ANDA: 2-pack configuration did not receive appropriate regulatory approval prior to release.

Terminated Unapproved drug Lupin Pharmaceuticals Inc. D-0837-2018
Class I · High risk

Limbrel500

Marketed Without An Approved NDA/ANDA: Based on the labeling claims, these products are unapproved drugs for which the safety and efficacy have not been established and, therefore, subject to recall.

Terminated Unapproved drug Primus Pharmaceuticals, Inc. NDC 68040-606-16 D-0347-2018
Class I · High risk

Limbrel250

Marketed Without An Approved NDA/ANDA: Based on the labeling claims, these products are unapproved drugs for which the safety and efficacy have not been established and, therefore, subject to recall.

Terminated Unapproved drug Primus Pharmaceuticals, Inc. NDC 68040-605-16 D-0346-2018